I. Background

In the **Federal Register** of April 19, 2000 (65 FR 20992), FDA's Center for Veterinary Medicine (CVM) announced plans to develop a prototypic risk assessment (RA) model that accounts for the transfer of resistance determinants from bacteria in food-producing animals to bacteria in humans. CVM also requested comments on their approach to the RA model, requested that scientific data and information relevant to the conduct of the RA be submitted, and indicated its intention to work with stakeholders to assess potential risks.

The outcome of our work is a document entitled "Draft Risk Assessment of Streptogramin Resistance in Enterococcus faecium Attributable to the Use of Streptogramins in Animals.' This draft risk assessment specifically addresses the link between the use of the streptogramin antimicrobial, virginiamycin, in food-producing animals and the development of resistance to the related streptogramins, quinupristin-dalfopristin, used to treat human enterococcal infections. Enterococcus bacteria include commensal strains normally present in the intestines of animals and man. This risk assessment focuses on the opportunistic pathogen Enterococcus faecium.

In an effort to better ensure broad awareness of this **Federal Register** notice, FDA will make copies available through the FDA Dockets Listserv (http://www.fda.gov/ohrms/dockets/FDAMAIL/DMBemaillist.htm). To be added to any of FDA's free e-mail subscription services go to: http://www.fda.gov. Click on "Subscribe to FDA's E-mail Lists", then follow the instructions provided.

II. Comments

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments on the draft guidance. Two copies of mailed comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The draft guidance and received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: November 13, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.
[FR Doc. 04–25979 Filed 11–23–04; 8:45 am]
BILLING CODE 4160–01–8

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the Substance Abuse and Mental Health Services Administration (SAMHSA) Drug Testing Advisory Board to be held in December 2004.

On December 7, the Board will meet in an open session from 8:30 a.m. to 9:30 a.m. The open session will include a Department of Health and Human Services drug testing program update, a Department of Transportation drug testing program update, and a Nuclear Regulatory Commission drug testing program update. Attendance by the public will be limited to space available. Public comments are welcome. Please communicate with the individual listed as contact below to make arrangements to comment or to request special accommodations for persons with disabilities.

The Board will also meet in closed sessions on December 7 from 9:30 a.m. to 4:30 p.m. and on December 8 from 8:30 a.m. until noon to develop the analytical and administrative policies for the final Revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Program that were published as proposed revisions in the Federal Register on April 13, 2004 (69 FR 19673). The submissions from 285 commenters have been made available to the public on the Web site http:// workplace.samhsa.gov. This portion of the meeting must be conducted in closed sessions since discussing such public comments in an open session and then developing the policies will significantly frustrate the Department's ability to develop the Final Notice of Revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The HHS Office of General Counsel made the determination that such matters are protected by exemption 9(B) of section 552b(c) of title 5 U.S.C. and therefore may be closed to the public.

A roster of the board members may be obtained from: Mrs. Giselle Hersh, Division of Workplace Programs, 1 Choke Cherry Road, Room 2–1035, Rockville, MD 20857, 240–276–2600 (telephone). The transcript of the open session will be available on the following Web site: http://workplace.samhsa.gov. Additional information for this meeting may be

obtained by contacting the individual listed below.

Committee Name: Substance Abuse and Mental Health Services, Administration Drug Testing Advisory Board.

Meeting Date: December 7, 2004; 8:30 a.m.–4:30 p.m., December 8, 2004; 8:30 a.m.–Noon.

Place: Residence Inn by Marriott, 7335 Wisconsin Avenue, Bethesda, Maryland 20814.

Type: Open: December 7, 2004; 8:30 a.m.–9:30 a.m., *Closed:* December 7, 2004; 9:30 a.m.–4:30 p.m., *Closed:* December 8, 2004; 8:30 a.m.–Noon.

Contact: Donna M. Bush, Ph.D., Executive Secretary, 1 Choke Cherry Road, Room 2–1035, Rockville, Maryland 20857, Email: Donna.Bush@samhsa.hhs.gov, 240– 276–2600 (telephone) or 240–276–2610 (fax).

Dated: November 15, 2004.

Toian Vaughn,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 04–26025 Filed 11–23–04; 8:45 am] BILLING CODE 4162–20–P

DEPARTMENT OF HOMELAND SECURITY

Office of the Secretary [Docket No. DHS-2004-0023]

Homeland Security Advisory Council

AGENCY: Office of the Secretary, DHS. **ACTION:** Notice of Federal Advisory Committee Meeting.

SUMMARY: The Homeland Security Advisory Council (HSAC) will hold a meeting for purposes of (1) receiving reports from Senior Advisory Committees; (2) receiving briefings from DHS staff on Departmental initiatives; and (3) holding roundtable deliberations and discussions among HSAC members. DATES: The Homeland Security

Advisory Council (HSAC) will hold its next meeting in San Diego, CA on Tuesday, December 14, 2004.

ADDRESSES: This meeting will be partially closed; the open portions of the meeting for purposes of (1) above will be held at the Westin Horton Plaza Hotel Library, 910 Broadway Circle, San Diego, CA 92101 from 9:30 a.m. to 11:30 a.m. The closed portions of the meeting, for purposes of (2) and (3) above will be held at the Westin Horton Plaza Hotel Harbor Room, 910 Broadway Circle, San Diego, CA 92101 from 8:30 a.m. to 9:20 a.m. and from 11:30 a.m. to 3:30 p.m.